A unified DNA- and RNA-based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors.
DNA-based NGS
RNA-based NGS
genomic variations
next-generation sequencing
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
27
09
2023
received:
11
07
2023
accepted:
15
10
2023
medline:
29
11
2023
pubmed:
25
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Targeted next-generation sequencing (NGS) is a powerful and suitable approach to comprehensively identify multiple types of variants in tumors. RNA-based NGS is increasingly playing an important role in precision oncology. Both parallel and sequential DNA- and RNA-based approaches are expensive, burdensome, and have long turnaround times, which can be impractical in clinical practice. A streamlined, unified DNA- and RNA-based NGS approach is urgently needed in clinical practice. A DNA/RNA co-hybrid capture sequencing (DRCC-Seq) approach was designed to capture pre-capture DNA and RNA libraries in a single tube and convert them into one NGS library. The performance of the DRCC-Seq approach was evaluated by a panel of reference standards and clinical samples. The average depth, DNA data ratio, capture ratio, and target coverage 250 (×) of the DNA panel data had a negative correlation with an increase in the proportion of RNA probes. The SNVs, indels, fusions, and MSI status were not affected by the proportion of RNA probes, but the copy numbers of the target genes were higher than expected in the standard materials, and many unexpected gene amplifications were found using D:R (1:2) and D:R (1:4) probe panels. The optimal ratio of DNA and RNA probes in the combined probe panel was 1:1 using the DRCC-Seq approach. The DRCC-Seq approach was feasible and reliable for detecting multiple types of variants in reference standards and real-world clinical samples. The DRCC-Seq approach is more cost-effective, with a shorter turnaround time and lower labor requirements than either parallel or sequential targeted DNA NGS and RNA NGS. It is feasible to identify multiple genetic variations at the DNA and RNA levels simultaneously in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Targeted next-generation sequencing (NGS) is a powerful and suitable approach to comprehensively identify multiple types of variants in tumors. RNA-based NGS is increasingly playing an important role in precision oncology. Both parallel and sequential DNA- and RNA-based approaches are expensive, burdensome, and have long turnaround times, which can be impractical in clinical practice. A streamlined, unified DNA- and RNA-based NGS approach is urgently needed in clinical practice.
METHODS
METHODS
A DNA/RNA co-hybrid capture sequencing (DRCC-Seq) approach was designed to capture pre-capture DNA and RNA libraries in a single tube and convert them into one NGS library. The performance of the DRCC-Seq approach was evaluated by a panel of reference standards and clinical samples.
RESULTS
RESULTS
The average depth, DNA data ratio, capture ratio, and target coverage 250 (×) of the DNA panel data had a negative correlation with an increase in the proportion of RNA probes. The SNVs, indels, fusions, and MSI status were not affected by the proportion of RNA probes, but the copy numbers of the target genes were higher than expected in the standard materials, and many unexpected gene amplifications were found using D:R (1:2) and D:R (1:4) probe panels. The optimal ratio of DNA and RNA probes in the combined probe panel was 1:1 using the DRCC-Seq approach. The DRCC-Seq approach was feasible and reliable for detecting multiple types of variants in reference standards and real-world clinical samples.
CONCLUSIONS
CONCLUSIONS
The DRCC-Seq approach is more cost-effective, with a shorter turnaround time and lower labor requirements than either parallel or sequential targeted DNA NGS and RNA NGS. It is feasible to identify multiple genetic variations at the DNA and RNA levels simultaneously in clinical practice.
Identifiants
pubmed: 37877443
doi: 10.1002/jcla.24977
pmc: PMC10681543
doi:
Substances chimiques
RNA
63231-63-0
Nucleic Acids
0
RNA Probes
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24977Subventions
Organisme : the National Human Genetic Resources Sharing Service Platform
ID : 2005DKA21300
Informations de copyright
© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Int J Cancer. 2019 Aug 1;145(3):649-661
pubmed: 30653256
Cancer Res. 2019 Jul 1;79(13):3163-3168
pubmed: 31196931
Pathol Oncol Res. 2017 Apr;23(2):225-234
pubmed: 27722982
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Front Oncol. 2022 Aug 24;12:992636
pubmed: 36091144
BMC Med. 2022 May 10;20(1):160
pubmed: 35534835
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
J Mol Diagn. 2019 Mar;21(2):183-185
pubmed: 30664939
Clin Cancer Res. 2023 Feb 1;29(3):571-580
pubmed: 36413222
Future Oncol. 2021 Sep;17(26):3529-3539
pubmed: 34254524
Nat Commun. 2019 Mar 27;10(1):1388
pubmed: 30918253
J Transl Med. 2021 Oct 17;19(1):433
pubmed: 34657620
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Thorac Oncol. 2019 Apr;14(4):737-741
pubmed: 30639620
J Mol Diagn. 2016 Mar;18(2):299-315
pubmed: 26801070
Oncologist. 2021 Nov;26(11):e1971-e1981
pubmed: 34286887
Br J Cancer. 2023 Apr;128(6):1148-1154
pubmed: 36572732
Genes Chromosomes Cancer. 2022 Jun;61(6):322-331
pubmed: 35066956
J Thorac Oncol. 2020 Jun;15(6):1000-1014
pubmed: 32014610
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Transl Lung Cancer Res. 2021 Nov;10(11):4221-4234
pubmed: 35004252
Clin Cancer Res. 2015 Aug 15;21(16):3631-9
pubmed: 25567908
Clin Cancer Res. 2023 Apr 14;29(8):1506-1514
pubmed: 36201167
N Engl J Med. 2022 Jan 20;386(3):241-251
pubmed: 34534430
Lung Cancer. 2021 Nov;161:55-59
pubmed: 34536732
Lung Cancer. 2020 Jan;139:207-215
pubmed: 31835042
Eur J Hum Genet. 2018 Mar;26(3):314-323
pubmed: 29367707
J Thorac Oncol. 2022 Jan;17(1):103-115
pubmed: 34455067
Diagnostics (Basel). 2020 Jul 27;10(8):
pubmed: 32726941
Lung Cancer. 2022 Apr;166:242-249
pubmed: 35378489
J Clin Lab Anal. 2023 Oct;37(19-20):e24977
pubmed: 37877443
Bioessays. 2020 Jul;42(7):e2000016
pubmed: 32307742
J Thorac Oncol. 2021 Jun;16(6):1017-1029
pubmed: 33676017
Mod Pathol. 2020 Jan;33(1):38-46
pubmed: 31375766
Thorac Cancer. 2020 Jul;11(7):1827-1834
pubmed: 32372482
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
J Cancer Res Clin Oncol. 2020 Jul;146(7):1867-1876
pubmed: 32221744
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Clin Cancer Res. 2019 Aug 1;25(15):4712-4722
pubmed: 31028088
Int J Mol Sci. 2021 Jun 22;22(13):
pubmed: 34206291